Company intelligence / Profile preview

ALM005 Applicant

Seoul, South Korea

Ownership: Private
Development stage: Other

Overview

Almedis is a South Korean biotechnology company focused on the development of novel therapeutics for gastrointestinal disorders. The company's lead candidate, ALM005, is a small molecule being investigated for the treatment of gastroesophageal reflux disease (GERD) and erosive esophagitis. Almedis aims to address unmet medical needs in the digestive health space through targeted clinical development programs. The company is currently advancing its pipeline through early-stage clinical trials to establish safety and efficacy profiles for its primary assets.

Therapeutic areas: Gastroenterology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on ALM005 Applicant.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALM005 Applicant.

Explore the full profile